More on MYGN
Data
Financials
Upcoming Events
News
Click line-items for a historical chart and %
| Net income | |
| Depreciation and amortization | |
| Loss on disposition of assets | -200K |
| Share-based compensation expense | 7.8M |
| Bad debt expense | 7.2M |
| Non-cash expense related to in-process research and development technology | |
| Unrecognized tax benefits | 400K |
| Excess tax benefit from share-based compensation | |
| (Gain) loss on sale of marketable investment securities | |
| Prepaid expenses | 7.8M |
| Trade accounts receivable | -5.9M |
| Other receivables | -1.8M |
| Inventory | -13M |
| Deferred income taxes | 3.2M |
| Accounts payable | -5M |
| Accrued liabilities | -9.5M |
| Deferred revenue | -1M |
| Net cash provided by operating activities | |
| Capital expenditures for equipment and leasehold improvements | -1.5M |
| Acquisition of Rules-Based Medicine, Inc. (see Note 14), net of cash acquired | -213M |
| Purchase of in-process research and development technology | |
| Purchase of other assets | |
| Proceeds from sale of intellectual property | |
| Purchases of marketable investment securities | |
| Proceeds from maturities and sales marketable investment securities | 88.7M |
| Net cash used in investing activities | |
| Net proceeds from common stock issued under share-based compensation plans | |
| Excess tax benefit from share-based compensation | |
| Repurchase and retirement of common stock | -21.3M |
| Net cash provided by financing activities | |
| Effect of foreign exchange rates on cash and cash equivalents | |
| Net increase (decrease) in cash and cash equivalents | 18.4M |
| Cash and cash equivalents at beginning of year | 68.5M |
| Cash and cash equivalents at end of year | 86.9M |
| Cash paid during the year for income taxes | |
| Fair value adjustment on marketable investment securities recorded to stockholders' equity | |
Entities mentioned with MYGN
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- JPMorgan | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
